SCHEMBL4959987

SCHEMBL4959987

O=C(O)Nc1ccc(NC(=O)c2ccccc2[N+](=O)[O-])cn1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.70
GAA P10253 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HTT P42858 2/20 0.59
NCOA1 Q15788 1/20 0.59
NCOA3 Q9Y6Q9 1/20 0.59
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
ALDH1A1 P00352 4/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
HPGD P15428 1/20 0.55
RAB9A P51151 1/20 0.55
P2RX1 P51575 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
SLC12A2 P55011 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4959978 1.00 KDM4E (0.70) KDM4EGAASMN1; SMN2HTTNCOA1
SCHEMBL31665065 0.85 KDM4E (0.62) KDM4EGAASMN1; SMN2HTTNCOA1
SCHEMBL4958310 0.84 GAA (0.71) GAASMN1; SMN2HTTNCOA1NCOA3
SCHEMBL4958300 0.84 GAA (0.71) GAASMN1; SMN2HTTNCOA1NCOA3
SCHEMBL6108383 0.82 HTT (0.61) KDM4EGAASMN1; SMN2HTTNCOA1
SCHEMBL4859758 0.82 KDM4E (1.00) KDM4EGAASMN1; SMN2HTTNCOA1
SCHEMBL31665600 0.82 KDM4E (0.68) KDM4EGAASMN1; SMN2HTTNCOA1
SCHEMBL890832 0.80 KDM4E (0.73) KDM4EGAASMN1; SMN2HTTNCOA1
SCHEMBL2438920 0.80 KDM4E (0.73) KDM4EGAASMN1; SMN2HTTNCOA1
SCHEMBL995085 0.79 GAA (0.77) GAASMN1; SMN2HTTNCOA1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008094909-A2 QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-07 WO disclosed